Apart from being proposed as an independent prognostic factor for all stages of CRC [54], one study proposed serum CEA as a robust prognostic marker for stage II tumour recurrence from the National Cancer Database (NCBD) data based on 45,449 patients during the years 2004-14 [55]. This evidence concerns the gene CEACAM5 and cancer.